Analysis Report on China Antibiotic IndustrySunFAITH China Ltd.June 29, 2007 5 Pages - SKU: CJFQ1542182 |
| Countries covered: China Anti-infective drugs and antibiotics have always been one of the major products of China pharmaceutical industry, as well as the drugs with the largest consumption volume for medical organizations in China. Because of huge continuous demand for antibiotic drugs from Chinese medical service system, the production and supply of antibiotic drugs are experiencing continuous prosperity. Although monopolization has formed in China antibiotics market currently, affected by the reform and rectification of medicare system and the change of Chinese medical market, Chinese antibiotics market will experience greater change and development. |
More China Prescription Drugs Reports
China's Pharmaceutical Industry 2011 by
China Research and Intelligence Co., Ltd.
This report describes the general development of China’s pharmaceutical industry in aspects of investment, production, sales, import & export, major prices and operations.
...
Chinese Markets for Hepatitis Drugs by
Asia Market Information & Development Company
China's demand for hepatitis drugs has grown at a fast pace in the past decade. In the next five years, both production and demand ...
China Pharmaceutical Industry Research and Forecast to 2016 by
AM Mindpower Solutions
EXECUTIVE SUMMARY The present report on “China Pharmaceutical Industry Research and Forecast to 2016” analyzes in detail the pharmaceutical industry environment with market sizing in terms ...
The Outlook for Pharmaceuticals in Brazil, Russia, India & China (pdf/xls) by
Espicom Healthcare Intelligence
These leading emerging economies represent a combined pharmaceutical market of US$132.2 billion. How have they emerged from the economic downturn? Where do commercial opportunities exist ...
The Pharmaceutical Market: China (pdf/xls) by
Espicom Healthcare Intelligence
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting ...
See all reports like this >>
More China Reports
D&B Country RiskLine Report: China by
Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
Country Report China February 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Country Report China January 2011 by
Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
D&B Country Report: China by
Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Wine - BRIC (Brazil, Russia, India, China) Industry Guide by
MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...
See all reports like this >>
Related Markets
Prescription Drugs Reports
- Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential
- Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management
- Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
- Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market
- Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program

